In another landmark trial, PRONOUNCE, patients with PCa and pre-existing ASCVD were randomized to receive the LHRH antagonist degarelix (N = 276) or the LHRH agonist leuprolide (N = 269), with the time to first adjudicated MACE (composite of death, MI, or stroke) through 1 year being the primary endpoint (71). Here, GNRH1 is linked to stroke disorder.